ILF Advisory Group members

Follow the links below for biographies and pictures of the current ILF Advisory Group members:

 

 




Brent Allan

Brent Allan

ILF Advisory Group member since 2015
Melbourne, Australia

Senior Program and Policy Advisor
Australasian Society for HIV Medicine & International Council of AIDS Service Organisations

 

Brent currently occupies two senior advisor positions focusing upon programs and policy for both the Australasian Society for HIV Medicine based in Sydney (Australia) as well as with the International Council of AIDS Service Organisations based in Toronto (Canada). He has been working in the community response to HIV/AIDS for over 25 years across a number of countries and has qualifications in health education, business, community services management as well as public and social health experience with local, state and federal governments, and internationally with the UNDP.

He is one of the founders of the Positive Leadership Development Institute Australia/New Zealand – an international collaboration between Canada and Australia focusing upon leadership development and resilience building for people living with HIV in the face of HIV stigma and discrimination.

As a gay man living with HIV for the past 19 years he has been active in efforts to build the capacity of people living with HIV through advocacy, education and representation, and he regularly provides technical assistance to global networks, governments, civil society and industry on matters of best practice in community-based services, research and development.

Brent is a passionate advocate for civil society and consumer representation in health service policy, programming and evaluation, and he currently occupies an advisory role for both the national and state governments in Australia on blood borne viruses, sexually transmissible infections as well as lesbian, gay, bisexual, transgender and intersex health and wellbeing.





Martin Auton

Martin Auton

ILF Advisory Group member since 2014
Geneva, Switzerland

Manager, Global Sourcing: Pharmaceuticals
Sourcing and Procurement of Health Products
The Global Fund to Fight AIDS, Tuberculosis and Malaria

Martin Auton is a pharmacist who worked in the United Kingdom for seven years and then spent the past 20 years working on access to health products in low- and middle-income countries across Africa, Asia, the Caribbean and eastern Europe. Dr Auton has worked for a number of organizations, including: the World Health Organization (based in eastern Europe and Africa); the United Nations (based in eastern Europe); Health Action International (based in the Netherlands); and now, the Global Fund (Geneva).




John Bannister

John Bannister

ILF Advisory Group member since 2014
Liverpool, UK

Global Health Regional Sales Director
Omega Diagnostics

 

Based in the UK, John is Regional Sales Director-Global Health for Omega Diagnostics, an AIM (London Stock Exchange’s international market for smaller growing companies) listed immunoassay and diagnostic company headquartered in Alva, Scotland with a strong distribution network in over 100 countries and offices in South Africa, Germany and India. Since joining Omega in 2014, John’s role has focussed on the market development of Omega’s expanding range of infectious disease diagnostic devices designed for use in low-resource settings that utilise mHealth connectivity for reading, interpretation and remote data access. In this role John coordinates with local and international NGOs, academic and technology stakeholders and national governments in the implementation of decentralised testing programmes for HIV (including coinfection) and neglected tropical diseases.

John graduated in microbiology from Coventry University and is a Member of the Society for Applied Microbiology. His early career spanned product development and research on antibiotic susceptibility and bacterial isolation methods. Subsequently, John has held a variety of commercial and leadership roles in private sector businesses and has over twenty years’ experience primarily involved with in vitro diagnostics, life sciences and analytical testing services. Prior to joining Omega, John was Commercial Director at LGC (formerly Laboratory of the Government Chemist), a science solutions leader in the pharmaceutical, agri/biotech and nutrition sectors that maintains a variety of statutory roles for UK government.




Linda-Gail Bekker

Linda-Gail Bekker

ILF Advisory Group member since 2013
Cape Town, South Africa

IAS President-Elect
IAS Paediatrics Priority Co-Chair

Deputy Director
Desmond Tutu HIV Centre
Institute of Infectious Disease and Molecular Medicine
Faculty of Health Sciences
University of Cape Town

Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, is Deputy Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, and Chief Operating Officer of the Desmond Tutu HIV Foundation. She is a physician scientist with a keen interest in HIV, tuberculosis and related diseases. Her doctoral work focused on the host response to tuberculosis both with and in the absence of HIV co‑infection. Subsequently, her research interests have expanded to include programmatic and action research around antiretroviral roll out and tuberculosis integration, prevention of HIV in women, youth and men who have sex with men. She has contributed to a number of publications emanating from the Desmond Tutu HIV Centre on topics relevant to the South African HIV and tuberculosis epidemics. In her role in the foundation, she is passionate about community development and engagement and actively explores new and innovative ways to tackle the challenge that is HIV.




Chris Beyrer

Chris Beyrer

ILF Advisory Group member since 2014
Baltimore, MD, USA

IAS President
IAS Key Populations Priority Co-Chair

Director
Johns Hopkins Training Program in HIV Epidemiology and Prevention Science

Director
Johns Hopkins Center for Public Health & Human Rights

Co-Principal Investigator
Johns Hopkins Center for AIDS Research

Associate Director
Center for Global Health

Professor
Johns Hopkins Bloomberg School of Public Health

Chris Beyrer MD, MPH, is Professor of Epidemiology, International Health and Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. He serves as Director of the Johns Hopkins Training Program in HIV Epidemiology and Prevention Science and as Founding Director of the Center for Public Health and Human Rights. He is the Associate Director of the Johns Hopkins Center for AIDS Research and of the university’s Center for Global Health. He currently serves as a member of the Men Who Have Sex with Men Working Group of the HIV Prevention Trials Network. He has extensive experience in conducting international collaborative research and training programmes in HIV/AIDS and other infectious disease epidemiology, infectious disease prevention research, HIV among key populations, and health and human rights.

As Director of the Johns Hopkins Fogarty AIDS International Training and Research Program, Dr Beyrer provided fellowships for more than 1,400 international scholars in HIV/AIDS prevention, research and treatment. He served as Field Director of the Thai PAVE and HIVNET studies from 1992 to 1996, based in Chiang Mai, northern Thailand, and has done extensive research in the epidemiology of HIV in Thailand, Burma, China, India and across southeast Asia, Russia and Kazakhstan, Malawi, South Africa and the USA. He is the author of the 1998 book, War in the Blood: Sex Politics and AIDS in Southeast Asia and Co‑Editor of Public Health and Human Rights: Evidence-Based Approaches. Dr Beyrer has served as advisor to the President’s Emergency Plan for AIDS Relief (PEPFAR), the HIV Vaccine Trials Network, the Office of AIDS Research of the US National Institutes of Health, the US Military HIV Research Program, the World Bank, the Royal Thai Army Medical Corps and the Thai Red Cross, as well as numerous other organizations. He is President of the International AIDS Society.




Duncan Blair

Duncan Blair

ILF Advisory Group member since 2015
Geneva, Switzerland

Director, Public Health Initiatives
Alere

Duncan Blair is the Director of Public Health Initiatives at Alere Inc., a position he has held since mid-2011. In this role Duncan’s responsibilities include global health policy and fostering collaboration between this major diagnostic industry partner and infectious disease diagnostics stakeholders. Duncan began his career as a biomedical scientist having completed a PhD in neuroscience and post-doctoral research in molecular and cellular biology. Leaving the research bench Duncan moved into public health initially as a diagnostics advisor to the National Center for HIV/AIDS, Dermatology and STDs (NCHADS) and the Clinton Health Access Initiative (at that time known as the Clinton HIV/AIDS Initiative; CHAI) in Cambodia. Since then Duncan has worked and collaborated with many organisations including ministries of health, CHAI, CDC-GAP, UNICEF, WHO-WPRO, the Secretariat of the Pacific Community (SPC) and others on the implementation, expansion, evaluation and quality improvement of diagnostic services related to HIV, STIs, tuberculosis and malaria in low-resource settings. Based in South East Asia for many years Duncan has extensive experience working with ministry, bi-lateral, multi-lateral, UN and NGO partners in Asia, Africa, the Caribbean and the Pacific both on the ground at the implementation level and at the national and international policy and guidance levels.




Samuel (Tony) Boova

Samuel (Tony) Boova

ILF Advisory Group member since 2016
Miami, USA

Director Alliance Development, High Burden HIV Markets
Beckman Coulter

Tony Boova works for Beckman Coulter Life Sciences, a Danaher company, within the Global Flow Cytometry Business Unit as Director Alliance Development. The function purpose is to develop alliances and partnerships with global organizations committed to fighting HIV/AIDS. These organizations include health policy, funding agencies, implementing partners, bi-laterals and Ministry of Health. Tony has 30 years’ experience in the diagnostics and life science sector, mostly in commercial leadership roles. Previous to his current function, he was the Commercial Director for Flow Cytometry in North America. Tony holds a bachelor degree in Management from Sigmund Weiss School of Business at Susquehanna University. He sees his work in Alliance Development as a privilege and opportunity to interface with extremely talented individuals committed to support for resource limited settings.

The past two years Tony has spent time learning and traveling in resource limited settings, primarily Africa. These experiences have inspired him to enhance his skills for increased effectiveness in public health matters. Recently, he enrolled in a global health graduate programme within Dornsife School of Public Health at Drexel University. He plans to earn a graduate degree in global health to improve his effectiveness for meaningful contributions. Tony is a Beckman Coulter dedicated resource for high burden HIV markets, primarily Africa, focused 100% on HIV/AIDS and co-infection epidemics. Beckman Coulter is renewing its commitment for HIV/AIDS diagnostics with a global strategy for participation centred on partnership and launching the CARES Initiative, which Tony is leading. The initiative intends to identify ways to contribute for programs that improve HIV services and systems delivery through Public Private Partnership. The CARES Initiative is focused on supporting the UNAIDS 90-90-90 targets, working through partnerships and alliances within the global community, identifying and addressing unmet needs related to the epidemic and providing innovative solutions to address the most pressing needs within countries with highest burden. It is a privilege for Tony to have the opportunity for participation in the ILF.




Celia Christie-Samuels

Celia Christie-Samuels

ILF Advisory Group member since 2010
Kingston, Jamaica

Professor and Chair
Paediatrics (Infectious Diseases, Epidemiology and Public Health)

Director
Vaccines Infectious Disease Centre and Kingston Paediatric and Paternal HIV/AIDS Programme for Clinical Research

Department of Obstetrics, Gynaecology and Paediatrics
Faculty of Medical Sciences, University of the West Indies

Celia DC Christie-Samuels has been Professor of Paediatrics in the Faculty of Medical Sciences at the University of the West Indies (UWI), Jamaica, and Consultant Paediatrician (Infectious Diseases, Epidemiology and Public Health) at the University Hospital of the West Indies (UHWI), Kingston, Jamaica, since 1999. In addition, Dr Christie-Samuels is the Director at the Vaccines Infectious Diseases Center UWI/UHWI and also Director of Kingston’s and then Jamaica’s Paediatric, Perinatal and Adolescent HIV/AIDS Program (2002 to date).

Dr Christie-Samuels holds a Doctorate of Medicine in Paediatrics from UWI and pursued post-doctoral fellowships in Paediatric Infectious Diseases and Epidemiology and later in Hospital and Molecular Epidemiology, from Yale University School of Medicine, USA. She has since completed her MPH degree from Johns Hopkins University, USA.

Dr Christie-Samuels’ research in the New England Journal of Medicine on reduced vaccine effectiveness during an epidemic of whooping cough among highly immunized children in Cincinnati, Ohio, USA, contributed to a change in whooping cough vaccine policy in that country. She has served as a consultant to various national bodies in the USA, such as the Center for Disease Control and Prevention in Atlanta, and was a member of the Food and Drugs Administration Anti-Infective Drugs Advisory Expert Panel.

She has received several awards. The most recent was the Lancet’s “Paper of the Year Award” for the best original medical research worldwide as a co-author on the International Pentavalent Rotavirus Vaccine Trial, published in the New England Journal of Medicine (2006). She also received the International Leadership Award from the Elizabeth Glaser Pediatric AIDS Foundation, USA. She has received several regional awards for research excellence, including an award from the Caribbean Public Health Agency and an award from UWI’s Vice Chancellor.

Dr Christie‑Samuels is a twice-elected member of the IAS Governing Council, representing Latin America and the Caribbean. Her current focus remains the elimination of vertical transmission of HIV and congenital syphilis, as well as paediatric, perinatal and adolescent HIV/AIDS. She works out of Jamaica.




Gavin Cloherty

Gavin Cloherty

ILF Advisory Group member since 2014
Green Oaks, IL, USA

Associate Director
Global Scientific Affairs
Global Surveillance Program
Abbott

Gavin Cloherty holds a PhD degree in Molecular Biology from the National University of Ireland, Galway. Dr Cloherty has worked for Abbott for more than fifteen years of which the first eleven were spent in research and development and scientific roles where he worked on the developed of infectious disease molecular tests and platforms. The last four years Dr Cloherty has worked in Scientific Affairs where he has focused on translational research for infectious disease diagnostics, establishing clinical studies, medical education, working to identify new applications for existing diagnostic tests and identifying potential new areas of interest for clinical diagnostics. Dr Cloherty is also keenly interested in ways of expanding the role of diagnostics to facilitate access to care in resource-limited settings.




Elliot Cowan

Elliot Cowan

ILF Advisory Group member since 2014
Rockville, MD, USA

Principal
Partners in Diagnostics

Elliot Cowan recently completed a 20-year career at the US Food and Drug Administration (FDA) in the regulation of in vitro diagnostic medical devices for infectious diseases. Beginning with regulatory issues surrounding blood donor screening tests for human T-lymphotropic virus, Dr Cowan assumed responsibility in 2000 for the regulation of the new generation of rapid HIV tests and the policy that guided their use. In 2006, he was appointed chief of the unit at the FDA that was responsible for leading the regulation of all blood donor screening tests and retroviral diagnostics used in the USA, including the first over-the-counter HIV test, approved in 2012. Dr Cowan was also a member of the Laboratory Technical Working Group for the President’s Emergency Plan for AIDS Relief (PEPFAR), serving as Chair of the HIV Diagnostics Subcommittee and providing technical assistance for laboratory quality assurance issues in PEPFAR focus countries. He advised the World Health Organization on the development of its Prequalification of Diagnostics Programme.

Dr Cowan is now Principal of Partners in Diagnostics, LLC, providing consulting on the global regulation of in vitro diagnostics to international public health agencies, procurement organizations, regulatory harmonization efforts, governmental bodies, philanthropic foundations and in vitro diagnostics manufacturers.

Dr Cowan received a BA from Williams College in 1977 and a PhD in Biology and Biomedical Sciences (Cellular, Developmental and Systemic Biology) from Washington University in St. Louis in 1983, followed by post-doctoral and research positions at the National Institutes of Health in Bethesda, MD, USA, before joining the FDA.




Nikhil Daftary

ILF Advisory Group member since 2017
Melbourne, Australia

Managing Director
Coral Healthcare

Nikhil Daftary is the Managing Director of Coral Healthcare Pty Ltd, which deals in condoms, medical ultrasound probe covers, personal lubricant, ultrasound gel and sterile rubber gloves. He is the brain child of the new brand of condoms in Australia called Moments Condoms. He has a Masters in Finance and also Certified Practising Accountant, Australia (CPA). He is also a Member of the Australian Institute of Company Directors. He has 15 years of experience working in various fields from chartered, manufacturing, Mayne Health (Symbion Health), ANZ Bank, Rio Tinto and Melbourne IVF (Virtus Health).

Nikhil has immense experience not only in Australian market, but also South-East Asia, Europe and India in areas of private health and condoms. He is also well connected with various international NGO’s related to HIV and AIDS, women’s health organisations in Australia, pharmaceuticals and health companies in Australia. He thrives on his company’s three pillars – Pleasure, Protection and Planning. Also, his main advocacy is towards women empowerment, requesting women to take control of their health in their own hands. His personal goal is aligned with UNAIDS to reduce HIV and AIDS by 2020, by easy access to condoms and more importantly help to eliminate new HIV infections among children by trying to ensure children have access to HIV treatment.




Colleen Daniels

Colleen Daniels

ILF Advisory Group member since 2014
Geneva, Switzerland

Community Engagement, Gender and Human Rights Advisor
Stop TB Partnership

Colleen Daniels has 17 years of experience as a project manager, technical officer and consultant in HIV/AIDS, tuberculosis, health, and conflict and fragile settings, working to deliver access to essential health services. She worked on programmes across 10 countries, lived and worked in Australia, Kenya, the Netherlands, Switzerland, Thailand, Tonga and the USA. She has successfully worked in a variety of settings, the NGO Treatment Action Group (TAG), the UN agency World Health Organization (WHO), international NGOs World Vision and Health Action International (HAI), the Tongan Government and the Australian Government (Departments of Immigration and AusAID). She is now Community Engagement, Gender and Human Rights Adviser at the Stop TB Partnership in Geneva, Switzerland.




Boniface Dongmo Nguimfack

Boniface Dongmo Nguimfack

ILF Advisory Group member since 2017
Geneva, Switzerland
Clearing House Manager, HTM/HIV/SIP/AMDS
WHO

Boniface is an economist by training and responsible for managing Access to AIDS Medicines and Diagnostics in the WHO HIV department. This portfolio is made of a transparency project (global price reporting to assess procurement performances, and drug regulatory status to assess in country registration of formulations), forecasting efforts (global demand forecasts of paediatric formulations, adult formulations, CD4, viral load, early infant diagnostics, and rapid diagnostics tests), and ARV use surveys (to identify which formulations and regimens are uses in first, second and third lines in countries). Boniface also provides technical assistance in both areas of Procurement and Supply Management (PSM) and Logistics Management and Information System (LMIS).




Philippe Duneton

Philippe Duneton

ILF Advisory Group member since 2015
Geneva, Switzerland

Deputy Executive Director
UNITAID

 




Samantha Giangregorio

Samantha Giangregorio

ILF Advisory Group member since 2016
Randburg, South Africa

Managing Director, Essential Health Care (EHC), Sysmex EMEA Region
Sysmex Corporation

 




Manuel Gonçalves

Manuel Gonçalves

ILF Advisory Group member since 2014
London, UK

Vice President, Head of External Affairs and Communication
ViiV Healthcare

Manuel Gonçalves received a MD degree at Lisbon Medical Faculty in 1977. He is Vice President and Head of External Affairs and Communication at ViiV Healthcare since 2009. Previously, he has been Vice President, GM, at GSK (1997-2009). He was also Vice Chairman of the Portuguese Pharma Industry Association in the same period. Since 2008, he is a Board Member of Lisbon Public University NOVA. Dr Gonçalves is a Member Elected of the Portuguese Medical Academy and a Member of the Bioethics Committee of Lisbon Medical Faculty. He worked in France, Portugal and the UK.




Catherine Hankins

Catherine Hankins

ILF Advisory Group member since 2009
Amsterdam, The Netherlands

Deputy Director, Science
Amsterdam Institute for Global Health and Development

Catherine Hankins, BA (Hons), MD, MSc, FRCPC, is a community medicine specialist who joined the Amsterdam Institute for Global Health and Development (AIGHD) from UNAIDS in Geneva, where she had been Chief Scientific Adviser from 2002 to 2012. At AIGHD, she oversees a range of HIV prevention research, including intervention and demonstration projects, as well as scientific knowledge translation. She participates actively in programme evaluation and research to inform policy development while teaching in the institute's Global Health Research Masters programme. In addition, she represents the institute in international fora.

Dr Hankins was editor of the science blog, HIV This Week (http://hivthisweek.unaids.org), co-managed the WHO-UNAIDS HIV Vaccine Initiative, and headed up UNAIDS's knowledge translation team focusing on ethical and participatory clinical trial conduct, communication of prevention trial results and support to country implementation of proven biomedical HIV prevention interventions, such as voluntary medical male circumcision. From 2002 to 2005, she supervised the UNAIDS care, prevention and epidemiology/economics teams, supporting expanded access to antiretroviral treatment and effective prevention strategies, estimating costs for care, prevention and impact alleviation, and tracking resource flows for HIV programming in low- and middle-income countries. She coordinated HIV technical inputs into the Global Fund Technical Review Panel and monitored research developments in HIV vaccines, microbicides, male circumcision and pre-exposure prophylaxis. From 2005 to 2007, she led the UNAIDS human rights, best practice and gender teams.

Dr Hankins is a fellow of the Royal College of Physicians of Canada and former President of the Canadian Association for HIV Research. She was a member of the Canadian National Advisory Committee on AIDS for eight years, chairing subcommittees on epidemiology, women and injection drug use. She was the principal investigator of the Canadian Women's HIV Study for a decade. She chaired a variety of Canadian research peer review committees and was principal investigator for studies involving prisoners, people who inject drugs and sex workers, as well as population-based epidemiological studies. She trained in medicine at the University of Calgary and in community medicine at the London School of Hygiene and Tropical Medicine. She was a consultant for UNDP, WHO, UNFPA and the Canadian International Development Agency.

Dr Hankins is a member of the Scientific Advisory Group of the US National Institutes of Health HIV Prevention Trials Network, the Scientific Advisory Board of the Global HIV Vaccine Enterprise, the WHO-UNAIDS HIV Vaccine Initiative Advisory Committee and the Global HIV Prevention Working Group. She is an Honorary Professor at the London School of Hygiene and Tropical Medicine, UK, in the Faculty of Epidemiology and Population Health, the current Chair of the Scientific Advisory Board of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and consultant Science Adviser at UNAIDS. Dr Hankins has authored or co-authored more than 200 peer-reviewed scientific papers.



Nick Hellmann

Nick Hellmann

ILF Advisory Group member since 2009
Seattle, WA, USA

Strategy and Science Advisor
Elizabeth Glaser Pediatric AIDS Foundation

Consultant
HIV-related issues, Bill & Melinda Gates Foundation

Nick Hellmann, MD, is the Strategy and Science Advisor at the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and a consultant to the Bill & Melinda Gates Foundation on HIV-related issues. From 2008 to 2014, he worked as the EGPAF Executive Vice President of Medical & Scientific Affairs, responsible for strategic oversight and direction of the foundation’s research initiatives and medical programmes focused on ending HIV/AIDS in children and providing HIV prevention, care and treatment services to children, women and families at more than 7,000 foundation-supported sites in 14 countries across the globe. Prior to joining EGPAF, Dr Hellmann worked at the Bill & Melinda Gates Foundation, where he led the HIV/AIDS and tuberculosis programme for two years. Before returning to the global health field, Dr Hellmann worked for 12 years in the pharmaceutical and biotechnology sectors at Bristol-Myers Squibb, Gilead Sciences, ViroLogic and Roche Molecular Systems on the development of drugs and diagnostic technologies for the treatment and management of HIV/AIDS and other serious infectious diseases.

Dr Hellmann graduated from the University of Kentucky College of Medicine in 1982 and completed his Internal Medicine residency and Infectious Diseases Fellowship training at the University of California, San Francisco, in 1988 prior to joining the UCSF medical faculty. During his faculty tenure at UCSF, Dr Hellmann lived and worked in Uganda, east Africa, for more than two years while studying heterosexual transmission of HIV and other sexually transmitted infections.




Philippe Jacon

Philippe Jacon

ILF Advisory Group member since 2015
Maurens-Scopont, France

President, Emerging Markets
Cepheid

Philippe Jacon joined Cepheid in January 2013. In his role of President, Emerging Markets, he leads the company’s growth in developing and emerging countries, including the high burden and developing countries (HBDC) programme which aims at giving access to a number of state-of-the-art molecular diagnostic tests to the populations in need, at concessional prices.

Prior to Cepheid, Philippe Jacon held the position of CEO of the Foundation for Innovative New Diagnostics (FIND) since October 2011. As such, he led the strategy of this not-for-profit, Geneva-based international organization to ensure fulfilment of its mission to “drive the development and early implementation of innovative diagnostic tests that have a high impact on patient care and disease control in low-resource settings”. Philippe Jacon joined FIND from EDMA (European Diagnostic Manufacturers Association) where he acted as the Director General ad interim since March 2011. Philippe is still Vice-President at EDMA and on the Board of Medtech Europe. Prior to EDMA, he spent most of his career with BD (Becton Dickinson and Co) in various positions and locations. Most notably, he was Worldwide President of BD Diagnostics – Diagnostic Systems and Worldwide President of BD Diagnostics – Microbiology Systems, both positions based in Baltimore, MD, USA.

Philippe Jacon has a Microbiologist Engineer degree from the Université de Bretagne Occidentale in France




Sharadd Jain

Sharadd Jain

ILF Advisory Group member since 2015
Mumbai, India

Head - Cipla Global Access
Cipla

Sharadd Jain is with Cipla as the Head of Cipla Global Access since 2012. He handles the global institutional business related to therapy areas of HIV, malaria, MDR–TB, reproductive health and hepatitis. Mr Jain has completed a Master’s in Business Management and International Trade and Marketing and has over 27 years’ experience in pharmaceuticals. He is well exposed to markets in Asia, Africa, Commonwealth of Independent States and Latin America in areas of public health across diverse geographies and portfolios. He is also well connected to various international organizations, procurement agencies, regulators, donor communities, NGOs and Ministries of Health involved in procurement for essential medicines. Mr Jain strives to add more value through collaborative partnership in areas of neglected and unmet needs of community at large in developing economies. His thinking is aligned to Cipla’s philosophy that “none shall be denied” access to lifesaving and essential drugs.




Mukul Jerath

Mukul Jerath

ILF Advisory Group member since 2017
Mumbai, India

General Manager - Global Institution Business
Lupin

 




Sandeep Juneja

Sandeep Juneja

ILF Advisory Group member since 2016
Geneva, Switzerland

Business Development Director
Medicines Patent Pool

Sandeep Juneja is the Business Development Director of the Medicines Patent Pool and has been with the MPP since 2011. Mr. Juneja leads MPP’s work with the pharmaceutical industry, and has negotiated and concluded deals with MPP’s originator and generic partners. He also leads a team that is responsible for scientific and technical matters, overseeing product development by generic partners, forecasting, impact measurement, and identifying and developing new therapy and technology areas for the MPP’s expansion.

Prior to his role at the MPP, Mr. Juneja spent 17 years in the pharmaceutical industry in diverse roles including developing and leading global access and research initiatives in HIV and malaria, profit and loss management, strategy, investor relations and mergers and acquisitions.

Mr. Juneja has published several articles, addressed international conferences, and served on several committees/panels on issues related to access to medicines. Mr. Juneja has a Masters in Business Administration, from IIFT-New Delhi and a Bachelors in Technology from the Indian Institute of Technology at Kanpur, India.




Ed Marins

Ed Marins

ILF Advisory Group member since 2015
Pleasanton, CA, USA

Director
Medical & Scientific Affairs, Virology
Roche Molecular Systems

Dr Marins received his MD degree at Faculdade de Ciências Médicas da Santa Casa de São Paulo and completed his medical training at the University of São Paulo where he concluded a Pediatric Residency and the Immunology & Allergy Specialization training. In 2008, he joined Roche Pharmaceuticals in Brazil to work with HIV and viral hepatitis. He moved to Roche Molecular Systems in California, USA, in 2014 as Global Director for Scientific Affairs in Virology.




Francesco Marinucci

Francesco Marinucci

ILF Advisory Group member since 2014
Norderstedt, Germany

Director, Essential Healthcare
Sysmex Corporation

Francesco Marinucci started his career in infectious diseases in 1998 as vice-director of the clinical laboratory of the Hospital Divina Providencia in Luanda, Angola. Since then, for the past 16 years he has spent close to 40% of his time in sub-Saharan Africa face to face with how far we have come “on the road” to diagnosing and treating HIV/AIDS in these settings.

Dr Marinucci is member of the Italian Society of Clinical Chemistry and European Specialist in Laboratory Medicine since 2004. He graduated in Chemistry from the University of Rome “La Sapienza”, and completed his internship and residency in Clinical Biochemistry at Sant’Andrea General Hospital, Rome. He obtained his PhD in Public Health and Microbiology from the same institution with a research study on the epidemiology and transmission patterns of HIV and other STDs among rural populations in sub-Saharan Africa.

From 2008 to 2012 Dr Marinucci directed the Global Laboratory Program at the Institute of Human Virology of the University of Maryland. In this position he provided strategic leadership and direction to the laboratory programme that the Institute of Human Virology implemented under a PEPFAR grant in 9 countries. Under Dr Marinucci’s leadership, the Global Laboratory Program supported 229 laboratories and trained hundreds of laboratory workers in the sub-Saharan African region, as well as in other PEPFAR countries in the Caribbean region.

At present, he is the Director of Essential Healthcare, Business Management Division at Sysmex Corporation. His main focus is strategy and business development related to access to quality diagnostic products for HIV, malaria, tuberculosis, and neglected diseases. He also serves as speaker of the German Healthcare Partnership for topics related to laboratory medicine in sub-Saharan Africa.




Kenneth Mayer

Kenneth Mayer

ILF Advisory Group member since 2014
Boston, MA, USA

IAS Governing Council member

Professor
Harvard Medical School and Harvard School of Public Health

Attending Physician and Director of HIV Prevention Research
Beth Israel Deaconess Medical Center

Founder, Co-Chair and Medical Research Director
The Fenway Institute

Kenneth Mayer’s clinical research career has focused on the natural history and transmission of HIV in the USA and in Asia, having developed some of the very first cohort studies and prevention interventions dealing with the AIDS epidemic. Dr Mayer published some of the earliest data describing the prevalence of HIV among men who have sex with men in the early 1980s and co-authored the first paper showing that antiretroviral drugs suppressed HIV replication in semen.

Dr Mayer was trained in Internal Medicine at Beth Israel Hospital (1977-80) and in Infectious Diseases and Molecular Epidemiology at Brigham and Women’s Hospital (1980-83). As the founding Medical Research Director of Fenway Health, he created a community health research programme that has developed an international reputation for its capability to conduct community-based peer‑reviewed research. He is currently a Professor at Harvard Medical School and Attending Physician and Director of HIV Prevention Research at Beth Israel Deaconess Hospital in Boston. Previously, he was a Professor of Medicine and Community Health at Brown University. As the Principal Investigator of the Brown-Tufts Fogarty International AIDS Training and Research grant for more than a decade, he has helped develop the research capabilities of almost 100 international investigators and co-authored some of the first papers describing the natural history of HIV in India. Since 1994, he has been the Principal Investigator of the only NIH-funded HIV Prevention Research Clinical Trials Unit in New England focusing on bio-behavioural prevention and chemoprophylaxis. He was the Co-Chair of an NIAID-funded protocol evaluating a community-based prevention intervention for African-American men who have sex with men. He is the co-author of more than 500 peer-reviewed publications, co-authored the first text on AIDS for the general public and has co-edited five academic texts.

Dr Mayer has served on the national boards of the HIV Medicine Association, the American Foundation for AIDS Research and the Gay and Lesbian Medical Association. He has received awards recognizing his work from the Governor of Massachusetts, the Rhode Island Medical Society, the American College of Physicians, the Infectious Disease Society of America and the American Foundation for AIDS Research. He served on the national CDC/HRSA HIV Advisory Board and is currently a member of the IAS Governing Council.



Perry Mohammed

Perry Mohammed

ILF Advisory Group member since 2012
London, UK

Global Medical Affairs Lead - HIV
Global Public Health
Johnson & Johnson

Perry is responsible for delivering on the Medical Affairs strategy for improving access to Janssen’s HIV medications and compounds in the developing world, in strong partnership with the Global R&D, Global Strategic Marketing & Market Access, and regional and local business units. His role also includes the development of partnerships with non-profit, government and non-government organizations like WHO, MSF and the Clinton Foundation, all with the aim of facilitation of HIV drug access to the patients that are in need. His current role encompasses Medical education and clinical trials, pre-approval access and compassionate use of our HIV compounds. He is also key partner and advocate of the New Horizons Initiative paediatric programme with the EGPAF. Under his leadership Janssen has trained hundreds of HCPs in the Sub-Saharan African region as well as other Least Developed Countries.

He has also been the Study Responsible Physician for multiple studies that are relevant to the geographical and therapeutic area of HIV including co-morbidities like Malaria. The SALIF study investigating the role of rilpivirine solely in the resource limited setting is a first for Janssen, going into countries where we have not conducted large scale trials in the past, has been one of his main projects to date.

During a recent secondment he gained experience working at the European & Developing Countries Trial Partnerships (EDCTP) in the networking department where part of his role was to foster closer relationships with industry partners in addressing the gaps for Poverty Related Diseases.

Having graduated from the University of the West Indies in 1998 with a MBBS degree, he worked in the public health service in Trinidad and Tobago as a junior doctor, gaining experience in internal medicine and emergency care. It was here his passion for HIV as a therapeutic area started, after treating patients for opportunistic infections and providing palliative care to those who had no access to HIV drugs. He continued his career as a HIV physician in the UK, working in the National Health Service where HIV drug access was not an issue. As a result Perry developed a broad perspective of the medical gaps and unmet needs for HIV drug access in resource limited settings. He joined Janssen in what was then Tibotec as a Medical Advisor in 2005, and since then has shown leadership in the field of Medical Affairs and Infectious diseases particularly HIV and TB.



Sébastien Morin

Sébastien Morin

Geneva, Switzerland

IAS-ILF Research Officer
International AIDS Society

Before joining the IAS, Sébastien Morin was headed for a career in basic research. In 2010, he completed a PhD in Biochemistry at Laval University in Quebec City, Canada, under the supervision of Stéphane Gagné. His thesis was entitled Motions, Order and Consistency: A Story Based on the Study of the Dynamics of the Class A β‑Lactamase PSE-4 by Nuclear Magnetic Resonance (available online). From 2010 to 2012, he worked as an EMBO post-doctoral fellow at the Biozentrum of the University of Basel, Switzerland, where he was part of the CHAARM (Combined Highly Active Anti-Retroviral Microbicides) consortium, which was aimed at the development of low-cost HIV preventive drugs. His project was focused on using biophysics tools for the study of the HIV co-receptor, CCR5, and its interactions with different ligands. Dr Morin has published 15 peer-reviewed scientific articles.

Throughout his career, Dr Morin has been involved in activities and programmes beyond research. These often complemented and improved conventional education programmes: widening the career prospects of researchers, teaching researchers leadership skills, developing open-source computer programs, and financially helping graduate students (by the introduction and management of a unique travel grant programme and by being a member of the International Relations Committee of the Biophysical Society). For several of these initiatives, limited funds were made available and sponsorships had to be obtained, which involved liaising with various partners and convincing them of the importance of the projects.

In February 2013, Dr Morin had the chance to use his diverse experience in a new adventure: he started working for the IAS in Geneva, Switzerland, as Research Officer for the Industry Liaison Forum (ILF). His work at the IAS is embedded in the activities of the HIV Programmes Department, and extends to cover all aspects of the work of the IAS.




Jeffrey Murray

Jeffrey Murray

ILF Advisory Group member since 2014
Silver Spring, MD, USA

Deputy Director, Division of Antiviral Products
U.S. Food and Drug Administration

Jeffrey S. Murray, MD, MPH, is Deputy Director of the Division of Antiviral Products (DAVP) at the US Food and Drug Administration. He has worked in the Division in various capacities for over 20 years. At DAVP, Dr Murray has reviewed and approved marketing applications for drugs to treat and/or prevent HIV, influenza, herpes viruses, hepatitis B and C. He has co-authored publications and FDA guidance documents for HIV drug development, HIV fixed dose combinations for the President’s Emergency Plan for AIDS Relief (PEPFAR) and the development of drugs for the treatment of Influenza and chronic hepatitis C. Dr Murray received his MD from The Ohio State University and his MPH in Epidemiology and Biostatistics from George Washington University in Washington, DC. He completed his internship, residency and chief residency in Internal Medicine at Riverside Methodist Hospitals in Columbus, followed by a fellowship in Infectious Diseases at the University of Cincinnati Medical Center. Dr Murray is board certified in Internal Medicine and Infectious Diseases.




Rahab Mwaniki

Rahab Mwaniki

ILF Advisory Group member since 2012
Nairobi, Kenya

Programme Officer
National Empowerment Network of People Living with HIV/AIDS

Rahab Mwaniki is a Public Health Specialist and Programme Officer at the National Empowerment Network of People Living with HIV/AIDS in Kenya. Her research has included work on HIV, PLHIV stigma and discrimination, maternal and child health, human rights, gender, nutrition, adolescent sexual reproductive health and key populations. She has also worked as a Programme Officer for the United Nations Joint Programme on AIDS (UNAIDS). Previously she worked as Programme Assistant / National Youth Secretary at the Kenya National Commission for UNESCO. She has published some researches in peer reviewed journals.




Ellen Paxinos

Ellen Paxinos

ILF Advisory Group member since 2017
Pleasanton, CA, USA

Global Director for Medical Affairs, Virology
Roche Molecular Systems

Dr Ellen Paxinos received her PhD degree from the Division of Biology and Medicine at Brown University, where she studied molecular evolution and population genetics. After her PhD, she was a Principal Scientist at ViroLogic (now Monogram Biosciences), developing and validating phenotypic and genotypic drug resistance assays for HIV and HCV, and oncology. Most recently, she worked at Pacific Biosciences, functioning as the Market Lead for Microbiology and Infectious Disease, building applications though key opinion leader collaborations. In March 2016, she joined Roche Molecular Systems in Pleasanton, California, USA as a Global Director for Medical Affairs in Virology, leading the medical strategy and the post-registration trials programme for Roche’s PCR-based assays for HIV-1, CMV, HBV, and HCV.




Jürgen Rockstroh

Jürgen Rockstroh

ILF Advisory Group member since 2014
Bonn, Germany

Professor of Medicine

Head
HIV Outpatient Clinic, University of Bonn

Jürgen Rockstroh, MD, is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. He earned a Doctor of Medicine degree from the Rheinische Friedrich-Wilhelms University of Bonn and completed his residency in the Department of Medicine, also at the University of Bonn. His department treats the world’s largest cohort of HIV-infected haemophiliacs.

In addition to his clinical practice, Dr Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV and hepatitis co-infection.

An active member of the HIV/AIDS treatment community, Dr Rockstroh was the Chairman of the German Clinical AIDS Working Group from 1998 to 2007. From 2007 to 2011, he was the elected President of the German AIDS Society. Since 2009, he has also been a member of the Executive Committee of the European AIDS Clinical Society (EACS). He chaired the organizing committee for the First and Second International Workshops on HIV and Hepatitis Co-Infection in Amsterdam in 2004 and 2005, and was on the international organizing committee for the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-Infected Patients in 2005. He was Co-Chair of the EACS conference in Cologne in 2009. Dr Rockstroh was a member of the Conference Coordinating Committee for the International AIDS Conference in Vienna in 2010 and was the IAS Scientific Programme Committee Co-Chair for the International AIDS Conference in Melbourne, Australia, in 2014. He chairs the hepatitis research activities in the European AIDS Treatment Network and EuroSIDA.

The German Society for Infectious Diseases awarded Dr Rockstroh and his co-authors the prize in clinical infectious diseases in 2002 and the national AIDS research prize in 2005. Dr Rockstroh has authored or co-authored more than 300 publications in peer-reviewed journals and more than 70 book chapters.



James Rooney

James Rooney

ILF Advisory Group member since 2006
Foster City, CA, USA

Vice President, Medical Affairs
Gilead Sciences

James F Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and, in 2004, became Vice President of Medical Affairs. From 2004 to 2006, he was also Vice President of Drug Safety and Public Health. Dr Rooney has been instrumental in the clinical development of the company's antiviral therapies, including treatments for HIV, hepatitis B and influenza. Dr Rooney also leads many of the company's clinical research activities in the developing world. He is the Gilead representative for the Bay Area Cross Sector Partners in Preparedness.

Prior to joining Gilead, Dr Rooney worked as a global project leader in HIV at Burroughs Wellcome and Glaxo Wellcome. He received his undergraduate degree at Harvard University in Cambridge, MA, USA, his medical degree and residency training in Internal Medicine at the University of Maryland Hospital in Baltimore, MD, USA, and his training in Infectious Diseases at the Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, MD, USA. Dr Rooney is board certified in Internal Medicine and Infectious Diseases and is a Fellow of the Infectious Diseases Society of America.




Owen Ryan

Owen Ryan

Geneva, Switzerland

IAS Executive Director
International AIDS Society

Owen Ryan has nearly 20 years of experience in HIV programming, policy and advocacy. While Deputy Director of Public Policy at amfAR, The Foundation for AIDS Research, he led a ground-breaking study of donor financing for HIV among key populations in partnership with the Center for Public Health and Human Rights at Johns Hopkins University. Before working at amfAR, Mr Ryan was a Program Officer at the Bill & Melinda Gates Foundation, where he directed the organization’s HIV policy and advocacy portfolio. He has served on the Board of Directors of the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Board of Funders Concerned About AIDS. He has been a dedicated advocate for the prevention, treatment and care of people living with or at risk of HIV, working at all levels of the HIV effort, including initiatives in Zimbabwe and Malawi.

Mr Ryan was awarded a Master’s degree in Public Health and a Master’s degree in International Affairs from Columbia University, NY, USA, and has a Bachelor of Arts degree in English Literature and Language



Paul Schaper

ILF Advisory Group member since 2017 (and previously from 2014-2016)
Washington DC, USA

Executive Director, Global Public Policy
MSD

 





Mauro Schechter

Mauro Schechter

ILF Advisory Group member since 2015
Rio de Janeiro, Brazil

Professor of Infectious Diseases, Projeto Praça Onze
Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro

Mauro Schechter is Professor of Infectious Diseases in the Department of Preventative Medicine at the Federal University of Rio de Janeiro, Brazil. He is also Adjunct Professor of Epidemiology at the Graduate School of Public Health at the University of Pittsburgh, and Associate in the Department of International Health in the Bloomberg School of Hygiene and Public Health at Johns Hopkins University. He earned his MD at the Federal University of Rio de Janeiro and his PhD at the London School of Hygiene and Tropical Medicine. He was a Research Associate at the Rockefeller University, New York, and a Research Assistant Professor at the New York University School of Medicine, USA.

Over the past three decades Dr Schechter has been involved in numerous leadership positions in international training, educational, and research initiatives, which provided him with a broad view of the magnitude and global societal impact of the HIV pandemic. This, in turn, made it clear to him that innovative approaches that integrate prevention and treatment, as well as greater collaboration between international initiatives and between the private and public sectors, are of paramount importance if we are to end the pandemic.

Dr Schechter serves (or has served) on numerous Advisory Boards and Committees, including the IAS Governing Council, the AIDS Clinical Trials Group (ACTG) Executive and Scientific Agenda Steering Committees, the Scientific Advisory Board of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), the Scientific Advisory Board of the South African Vaccine Initiative (SAAVI), the Clinical Trials Committee of the International AIDS Vaccine Initiative (IAVI), and the Consensus Panels on Antiretroviral Therapy of the World Health Organization (WHO), the International AIDS Society-USA (IAS-USA) and the Brazil Ministry of Health. He is the Epidemiology Section Editor of the AIDS Research and Human Retroviruses Journal. His primary research interest is preventing and treating HIV/AIDS in different settings. He has conducted several large, collaborative international studies.




Matthias Stahl

Matthias Stahl

ILF Advisory Group member since 2016
Geneva, Switzerland

Group Lead, Medicines Assessment, WHO Prequalification Team - Medicines
WHO

Physician, specialist of clinical pharmacology, with a background in pharmacovigilance and pharmaco-epidemiology at the Swedish Medical Products Agency, followed by a number of years in big pharma in UK, Belgium and Switzerland (early phase clinical trials, experimental medicine and drug safety). Since 2004 at WHO, heading up the medicines assessment team in the Prequalification of Medicines Programme.




Wim Vandevelde

Wim Vandevelde

ILF Advisory Group member since 2015
Cape Town, South Africa

Liaison Officer
Global Network of People Living with HIV

For over a decade Wim Vandevelde has been committed to full time action on HIV, Hepatitis and TB treatment advocacy, education and medical research.

Elected to the Board of Directors of the European AIDS Treatment Group (EATG) in 2004, he served as its Chairman until May 2009. Since then Wim has chaired the Research working group of the EATG, the European Community Advisory Board (ECAB) and its Policy Working Group. EATG is the foremost HIV patient advocate group in Europe, representing over 35 countries and working on HIV treatment and biomedical prevention research.

Wim is a founder and past President of the Portuguese HIV treatment group, GAT, and is a member of the Core Group of the Stop TB Partnership Working Group on New Drugs. He has served as a member of the HIV/AIDS Civil Society Forum and the Think Tank of the European Commission (DG SANCO) and served two terms on the Steering Committee of AIDS Action Europe, the European platform of AIDS Service Organizations. He currently chairs the Global TB Community Advisory Board.

Since June 2015 Wim commenced in the Community Development department at the Global Network of People living with HIV (GNP+). His role focuses mostly on assisting the Communities Delegation to the UNITAID Board, acting as Liaison Officer.

Prior to his health advocacy work, Wim worked in the banking industry in Belgium, Spain and Portugal. A native of Bruges, Belgium, Wim speaks Dutch, French, English and Portuguese.




Denise van Dijk

Denise van Dijk

ILF Advisory Group member since 2015
Utrecht Area, The Netherlands

President, Global Public Health Sector Division
Female Health Company

Denise van Dijk is the President, Global Public Health Sector Division for the Female Health Company. She holds an MPhil in International Development Studies from the University of Cambridge and has been working in the development field with a focus on education and sexual and reproductive health and rights for most of her career, especially focussed on the African continent. She is responsible for both public and private sales, programmes and partnerships on both the European and African continents. Her main job is working together with Ministries of Health, and large global agencies in order to implement sustainable and context-specific female condom programmes in African countries, combating the spread of HIV/AIDS and other STIs as well as to assist in family planning options for women, ensuring female empowerment through choice.

The Female Health Company manufactures, markets and sells the FC2 Female Condom. FC2 is the only female-controlled product approved by the U.S. Food and Drug Administration (FDA) and cleared by the World Health Organization (WHO) that provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. For sexually active couples, male and female condoms are the only two FDA approved and marketed products that prevent the transmission of HIV/AIDS through sexual intercourse. The Company’s customers are primarily large global agencies, non-government organizations, Ministries of Health and other government agencies which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programmes. Since the company began distributing FC2 in 2007, it has been shipped to 144 countries world-wide.




Colleen Wegzyn

Colleen Wegzyn

ILF Advisory Group member since 2017
Chicago, USA

Medical Affairs, HIV/Neonatology, Global Therapeutic Area Lead
AbbVie

Colleen is the Therapeutic Area Lead for HIV & Neonatology at AbbVie. She earned a Bachelor’s degree in Chemistry and Doctor of Pharmacy degree from Wayne State University, Detroit, USA. She completed postdoctoral training and certification in Infectious Disease. She served as a clinical pharmacist specialist at the University of Colorado Hospital, and served as adjunct faculty at the University of Colorado, School of Pharmacy. Colleen joined Abbott/AbbVie in 2006 and held Medical Affairs positions in the therapeutic areas of HIV, HCV, neonatology and dermatology. She is knowledgeable in clinical research and data generation, through her experience in development and execution of Phase IIIb‐IV trials, epidemiology research, and real world evidence data generation, of which have resulted in several peer reviewed scientific publications.